In this special report, eyeforpharma examines how pharma can identify, engage with, and benefit from key opinion leaders (KOLs)
Six novel ways pharma can identify and engage with key opinion leaders (KOLs)
Phil Taylor explores how pharma’s relationship to key opinion leaders is changing—for the better
Kevin Appareti, global director for Medical Science Liaison at Philips Healthcare, explains how to motivate KOLs and how to measure their value
Kevin Appareti, Global Director Medical Science Liaison at Philips Healthcare, gives a short but useful interview on his company's approach to KOL engagement
Neil Kendle, director of Kendle Healthcare, on how to manage relationships with non-traditional and non-clinical KOLs
Emma D'Arcy, senior digital consultant with Complete Digital, on making pharma's relationships with key opinion leaders (KOLs) work
Phil Taylor reports on the commercial and scientific opportunities facing medical scientific liaisons (MSLs)
Medical scientific liaisons (MSLs)—the people physicians talk to when they have scientific questions—have traditionally been separated from the marketing and commercial functions. Should the boundaries between the two functions be broken down?
Andrew Tolve investigates the opportunities and challenges for pharma’s use of cloud computing
Dr. Andre K. Bates explains how focusing on corporate integrity and responsibility yields real business benefits
Pharma is increasingly turning to corporate social responsibility (CSR) to repair its damaged reputation and boost the bottom line. Andrew Tolve reports
Alan Crofts outlines the flexible market access strategies needed to address the needs of clinical and non-clinical decision makers
Johanna Jarvis, head of advocacy at Wyeth, on how to incorporate opinion leaders into marketing strategy
Key opinion leaders should be guides and counsels, not company junkies
Why we need to keep Key Opinion Leaders at a safe distance
Stephen Dodge, Executive Director of the East Field Medical Affairs Organisation at Novo Nordisk, answers questions about how KOL management will evolve over the coming years
30% of pharma executives expect business as usual, as they admit to expecting blockbuster-type...
Lucy Brake speaks to Mike Rea, CEO of IDEA Pharma, about how he believes real world evidence...
Dr Jean-Michel Cosséry, the new UK managing director and vice president for its Northern Europe hub...